<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2018.85075</article-id><article-id pub-id-type="publisher-id">ACM-25860</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20180500000_34459450.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  长链非编码RNA MEG3在肿瘤发生中的研究进展
  Research Advancements of Long Non-Coding RNA MEG3 in Tumor
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>周</surname><given-names>晶</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>田</surname><given-names>野</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>泰州市人民医院肿瘤科，江苏 泰州</addr-line></aff><aff id="aff3"><addr-line>泰州市人民医院普外科，江苏 泰州</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>09</day><month>07</month><year>2018</year></pub-date><volume>08</volume><issue>05</issue><fpage>454</fpage><lpage>459</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    长链非编码RNA(lncRNA)是一类长度超过200 nt (核苷酸)的功能性RNA分子，以RNA的形式在多种层面(表观遗传学、转录水平、转录后水平等)上调控基因的表达。在肿瘤的发生、发展过程中发挥着重要的作用。母系表达基因MEG3是第一个被发现具有肿瘤抑制功能的lncRNA。众多研究表明lncRNA MEG3表达于多种正常组织，而在大多数肿瘤组织或肿瘤细胞株中不表达。本文总结了lncRNA MEG3在研究方面取得的进展，主要就lncRNA MEG3在肿瘤发生发展中的作用作一综述。
    Long non-coding RNAs (lncRNAs, &gt; 200 nt) were reported more recently. Most lncRNAs play im-portant biological roles in tumorigenesis through different mechanisms including epigenetic modification, alternative splicing, RNA decay, and post-translation modification regulation. MEG3, an imprinted gene, maternally expressed in humans, has been first identified as a tumor suppres-sor. The expression of MEG3 is lost or markedly reduced in several primary human tumors. In this review, we review the latest advancement of MEG3 in tumorigenesis. 
  
 
</p></abstract><kwd-group><kwd>长链非编码RNA，MEG3，肿瘤, Long Non-Coding RNA</kwd><kwd> MEG3</kwd><kwd> Tumor</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>长链非编码RNA MEG3在肿瘤发生中的 研究进展<sup> </sup></title><p>周晶<sup>1</sup>，田野<sup>2</sup></p><p><sup>1</sup>泰州市人民医院肿瘤科，江苏 泰州</p><p><sup>2</sup>泰州市人民医院普外科，江苏 泰州</p><p><img src="//html.hanspub.org/file/2-1570598x1_hanspub.png" /></p><p>收稿日期：2018年6月6日；录用日期：2018年7月5日；发布日期：2018年7月12日</p><disp-formula id="hanspub.25860-formula10"><graphic xlink:href="//html.hanspub.org/file/2-1570598x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>长链非编码RNA(lncRNA)是一类长度超过200 nt (核苷酸)的功能性RNA分子，以RNA的形式在多种层面(表观遗传学、转录水平、转录后水平等)上调控基因的表达。在肿瘤的发生、发展过程中发挥着重要的作用。母系表达基因MEG3是第一个被发现具有肿瘤抑制功能的lncRNA。众多研究表明lncRNA MEG3表达于多种正常组织，而在大多数肿瘤组织或肿瘤细胞株中不表达。本文总结了lncRNA MEG3在研究方面取得的进展，主要就lncRNA MEG3在肿瘤发生发展中的作用作一综述。</p><p>关键词 :长链非编码RNA，MEG3，肿瘤</p><disp-formula id="hanspub.25860-formula11"><graphic xlink:href="//html.hanspub.org/file/2-1570598x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2018 by authors and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/2-1570598x7_hanspub.png" /> <img src="//html.hanspub.org/file/2-1570598x8_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>母系表达基因(materally expressed gene 3, MEG3)，是一种印迹基因，定位于染色体14q32.3，是由Miyoshi等人于2000年首次发现的小鼠母体印记基因Glt2的人类同系物 [<xref ref-type="bibr" rid="hanspub.25860-ref1">1</xref>] 。lncRNA MEG3是第一个被发现具有肿瘤抑制功能的lncRNA(long non-coding RNA)，在许多正常组织中表达，而在多种人类肿瘤和肿瘤细胞中表达缺失 [<xref ref-type="bibr" rid="hanspub.25860-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.25860-ref3">3</xref>] 。本文就lncRNA MEG3的功能研究进展及lncRNA MEG3在肿瘤发生发展中的作用作一综述。</p></sec><sec id="s4"><title>2. 长链非编码RNA</title><p>人类基因组中约有98%的转录产物为非编码RNA (noncoding RNA, ncRNA)，在生长发育、肿瘤发展等过程中起着广泛而重要的作用 [<xref ref-type="bibr" rid="hanspub.25860-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.25860-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.25860-ref6">6</xref>] 。非编码RNA包括短链非编码RNA和长链非编码RNA。短链非编码RNA，如miRNA和siRNA的功能和临床意义已被证实，而长链非编码RNA(lncRNAs, &gt;200 nt)的功能和临床意义已成为最近研究的热点。新近研究发现，lncRNAs并不编码蛋白，而是以RNA的形式在多种层面上(表观遗传调控、转录调控以及转录后调控等)调控基因的表达水平 [<xref ref-type="bibr" rid="hanspub.25860-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.25860-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.25860-ref9">9</xref>] 。</p><p>已有众多研究证实，lncRNAs在肿瘤的形成过程中发挥着重要的生物学作用。LncRNA差异表达于正常组织与肿瘤中，特异性的lncRNA可作为肿瘤的预测因子。例如，lncRNA HOTAIR在乳腺癌中表达显著上调，沉默其表达后影响了乳腺癌细胞的侵袭能力，且与乳腺癌患者的预后不良密切相关 [<xref ref-type="bibr" rid="hanspub.25860-ref10">10</xref>] ；lncRNA MALAT1在NSCLC中表达显著上调并促进了NSCLC细胞的侵袭和转移，可作为NSCLC患者预后不良的分子指标 [<xref ref-type="bibr" rid="hanspub.25860-ref11">11</xref>] 。</p><p>LncRNA MEG3是第一个被发现有肿瘤抑制作用的lncRNA。LncRNA MEG3表达于多种正常组织，特别在脑组织呈现高表达，然而在肿瘤组织及一些肿瘤细胞株中不表达，提示lncRNA MEG3具有肿瘤抑制因子的作用 [<xref ref-type="bibr" rid="hanspub.25860-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.25860-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.25860-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.25860-ref15">15</xref>] 。</p></sec><sec id="s5"><title>3. lncRNA MEG3来源</title><p>Zhang等人 [<xref ref-type="bibr" rid="hanspub.25860-ref2">2</xref>] 为了明确垂体腺瘤的分子生物学发病机制，运用cDNA代表性差异分析法(cDNA-RDA)方法比较了正常垂体组织和无功能性垂体腺瘤间基因表达的差异，其中下调最为明显的四种基因分别是GADD45-γ，组蛋白剪切酶6，DLKl和MEG3。印记基因MEG3在正常人促性腺激素细胞中有表达，而在促性腺激素细胞起源的无功能性垂体腺瘤中不表达；Northern Blot和RT-PCR分析进一步表明：lncRNA MEG3在功能性垂体腺瘤及许多细胞株中也不表达。基因分析表明：lncRNA MEG3定位于染色体14q32.3。Miyoshi等 [<xref ref-type="bibr" rid="hanspub.25860-ref1">1</xref>] 于2000年首次发现lncRNA MEG3基因是小鼠基因Gtl2的同系物。LncRNA MEG3或Gtl2基因与另一个印记基因Dlk1密切相关 [<xref ref-type="bibr" rid="hanspub.25860-ref16">16</xref>] 。Dlk1编码包含6个表皮生长因子重复序列的跨膜蛋白，但lncRNA MEG3或Glt2基因的功能还不明确。</p></sec><sec id="s6"><title>4. lncRNA MEG3特点</title><p>LncRNA MEG3，一种母系表达的印迹基因，编码长度为~1600个nt的长链非编码RNA的表达(17)。LncRNA MEG3具有10个外显子组成的单拷贝印迹基因，由于不同的剪接方式共发现了12个表型，每个表型包含共同的外显子1-3和8-10，在外显子4-7有不同的链接方式；12个lncRNA MEG3表型均显示3个明显的二级结构域 [<xref ref-type="bibr" rid="hanspub.25860-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.25860-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.25860-ref18">18</xref>] 。</p><p>功能上，lncRNA MEG3可以刺激肿瘤抑制因子p53介导的转录活性，使p53蛋白在细胞内聚集，降低了p53负性调节因子MDM2蛋白的表达 [<xref ref-type="bibr" rid="hanspub.25860-ref17">17</xref>] ，同时选择性地激活p53的下游目标基因GDF15(TGF-β家族成员，具有抑增殖作用 [<xref ref-type="bibr" rid="hanspub.25860-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.25860-ref20">20</xref>] [<xref ref-type="bibr" rid="hanspub.25860-ref21">21</xref>] ；而p53的另一个众所周知的靶基因p21<sup>CIPI</sup>并不受lncRNA MEG3的影响 [<xref ref-type="bibr" rid="hanspub.25860-ref17">17</xref>] 。同时，lncRNA MEG3本身的表达也受表观遗传学的控制，在多种肿瘤中lncRNA MEG3存在异常的CpG甲基化 [<xref ref-type="bibr" rid="hanspub.25860-ref22">22</xref>] [<xref ref-type="bibr" rid="hanspub.25860-ref23">23</xref>] 。</p></sec><sec id="s7"><title>5. lncRNA MEG3与肿瘤的研究进展</title><p>除了正常的垂体组织，lncRNA MEG3在脑、肾上腺以及胎盘组织中均高表达 [<xref ref-type="bibr" rid="hanspub.25860-ref2">2</xref>] ，而在几乎全部无功能性垂体瘤、大部分功能性垂体瘤、肝癌以及神经胶质瘤等肿瘤中lncRNA MEG表达是缺失或明显下调的 [<xref ref-type="bibr" rid="hanspub.25860-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.25860-ref20">20</xref>] [<xref ref-type="bibr" rid="hanspub.25860-ref24">24</xref>] 。</p><sec id="s7_1"><title>5.1. lncRNA MEG3与无功能性腺瘤</title><p>垂体腺瘤占颅内肿瘤的10%，人群发病率为20%，无功能性垂体腺瘤(non-functional adenomas, NAFs)体肿瘤的30% [<xref ref-type="bibr" rid="hanspub.25860-ref25">25</xref>] 。NAFs的细胞起源差异很大，确诊时往往肿瘤体积较大，肿瘤压迫致临床常继发出现垂体功能低下，视力下降及视野缺损等症状 [<xref ref-type="bibr" rid="hanspub.25860-ref26">26</xref>] 。尽管NAFs大多数是良性肿瘤，但约5%~35%的肿瘤呈侵袭性生长，破坏硬膜、颅骨，侵入蝶窦或海绵窦；极少数是恶性肿瘤，转移到中枢神经系统以外的其他区域生长 [<xref ref-type="bibr" rid="hanspub.25860-ref25">25</xref>] [<xref ref-type="bibr" rid="hanspub.25860-ref26">26</xref>] 。</p><p>Zhang等人 [<xref ref-type="bibr" rid="hanspub.25860-ref2">2</xref>] 运用cDNA-RDA方法比较了正常垂体组织和NAFs间基因表达的差异，发现lncRNA MEG3下调较为明显；为了进一步验证lncRNA MEG3在NAFs中的表达，他们运用RT-PCR检测了在五种正常脑垂体以及八种促性腺激素来源的NAFs中lncRNA MEG3的表达。在正常脑垂体中lncRNA MEG3均有表达，而在NAFs中lncRNA MEG3无表达；同时又通过qRT-PCR检测了16例正常垂体和50例额外的促性腺激素细胞来源的NAFs。在19例NAFs中lncRNA MEG3的表达水平少于正常垂体的2%。这些数据表明lncRNA MEG3表达在促性腺激素细胞来源的NAFs中是缺失的；同样检测了LHβ或FSHβ表达阴性的肿瘤，发现这些肿瘤中MEG3的表达类似于促性腺激素细胞来源的NAFs。</p><p>所有结果表明NFAs中lncRNA MEG3表达缺失是普遍现象。</p></sec><sec id="s7_2"><title>5.2. lncRNA MEG3与脑膜瘤</title><p>脑膜瘤占所有中枢神经系统肿瘤的15%~25%。脑膜瘤生长比较缓慢，分期为I级的脑膜瘤被认为是良性的，但是I期脑膜瘤的复发会导致重要结构的挤压，从而导致临床神经系统功能的损伤；II期或III期脑膜瘤发病率低于20%，却具有较强的侵袭能力，随着发病率及死亡率的增加具有了高的复发风险 [<xref ref-type="bibr" rid="hanspub.25860-ref27">27</xref>] 。</p><p>Zhang等人 [<xref ref-type="bibr" rid="hanspub.25860-ref19">19</xref>] 报道lncRNA MEG3与脑膜瘤的病理发生、临床进展相关，在正常脑膜细胞高表达，而在大多数人脑膜瘤组织或细胞株中不表达，同时lncRNA MEG3表达的缺失与肿瘤的分级存在强烈的相关性。另外，lncRNA MEG3基因启动子在脑膜瘤CpG甲基化增加。从功能上看，lncRNA MEG3抑制脑膜瘤细胞的DNA合成及细胞集落的形成，而且刺激p53的转录活化。</p></sec><sec id="s7_3"><title>5.3. lncRNA MEG3与肝细胞癌</title><p>肝细胞癌(hepatocellular carcinoma, HCC)是全世界发病率迅速上升的恶性肿瘤之一，目前肝移植是治疗早期肝癌最有效的根治方法，但是术后复发是影响肝癌患者远期生存最主要的问题。</p><p>Braconi等人 [<xref ref-type="bibr" rid="hanspub.25860-ref24">24</xref>] 研究表明，与正常肝细胞相比，lncRNA MEG3在肝癌细胞中下调了210倍；过表达lncRNA MEG3后显著地抑制了肝癌细胞的生长，诱导了肝癌细胞的凋亡。MiR-29能够通过启动子区的超甲基化来调控lncRNA MEG3的表达并增加lncRNA MEG3的表达水平，提出了lncRNA MEG3将会成为肝细胞癌干扰治疗中的一个潜在的下游靶点。</p></sec><sec id="s7_4"><title>5.4. lncRNA MEG3与膀胱癌</title><p>膀胱癌发病率位于男性恶性肿瘤的第四位 [<xref ref-type="bibr" rid="hanspub.25860-ref28">28</xref>] 。分子及病理研究将膀胱癌至少分为两大类：泌尿道上皮肿瘤是非侵袭性的乳突状肿瘤，发生较多但是较少进展；而侵袭性的膀胱癌进展非常快，病人往往预后不良，且五年生存率只有50% [<xref ref-type="bibr" rid="hanspub.25860-ref29">29</xref>] [<xref ref-type="bibr" rid="hanspub.25860-ref30">30</xref>] 。因此，研究其分子机制就显得尤为重要了。</p><p>Ying等人 [<xref ref-type="bibr" rid="hanspub.25860-ref31">31</xref>] 研究发现，相比于正常组织，lncRNA MEG3在膀胱癌组织中的显著减少，且在肿瘤组织中的自噬活性明显增强，同时体内研究发现lncRNA MEG3和LC3-II (一种自噬标记物)之间具有负性相关性；进一步在体外实验中发现lncRNA MEG3抑制了自噬活性，而敲除lncRNA MEG3表达后激活了自噬活性；下调lncRNA MEG3表达后会抑制细胞的凋亡，而自噬的抑制剂能够解救lncRNA MEG3敲除所导致的细胞凋亡，更重要的是自噬抑制剂消除了lncRNA MEG3敲除后所导致的细胞增殖。</p><p>以上数据表明，在膀胱癌中下调lncRNA MEG3后会激活自噬从而增强细胞的增殖。</p></sec><sec id="s7_5"><title>5.5. lncRNA MEG3与其他肿瘤</title><p>另外一些研究显示，lncRNA MEG3与神经胶质瘤增殖相关，lncRNA MEG3的过表达抑制细胞增殖，诱导细胞凋亡，并且与p53基因的活化有关 [<xref ref-type="bibr" rid="hanspub.25860-ref20">20</xref>] ；在对多发性骨髓瘤、急性髓性白血病、骨髓增生异常综合症病例lncRNA MEG3基因启动子差异性甲基化区的甲基化状态分析发现，在57%的多发性骨髓瘤存在异常的甲基化谱，并且甲基化谱与疾病的亚型和疾病的阶段具有相关性，同时发现，在34.9%MDS和47.6%的急性骨髓性白血病有异常甲基化，但在甲基化状态与核型和预后评分系统间没有重要联系然而，采用生存分析法发现，lncRNA MEG3启动子异常高甲基化的急性骨髓性白血病、骨髓增生异常综合症病例总的幸存率下降 [<xref ref-type="bibr" rid="hanspub.25860-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.25860-ref32">32</xref>] 。</p></sec></sec><sec id="s8"><title>6. 展望</title><p>一个好的肿瘤抑制因子应该至少满足以下三个标准：1) 在肿瘤中功能性的失活；2) 过表达后会在体内外抑制肿瘤生长；3) 敲除了这些基因后会导致肿瘤的形成或老鼠模型中发育的缺陷。许多研究已经报道，lncRNA MEG3在多种肿瘤组织及肿瘤细胞中表达缺失。过表达lncRNA MEG3后能够抑制肿瘤细胞的增殖，诱导细胞的凋亡。lncRNA MEG3的功能可能是通过肿瘤抑制因子p53来调节。众多研究表明lncRNA MEG3是一个新型的lncRNA肿瘤抑制因子。尽管对lncRNA MEG3作用的分子机制的认识还相对有限，但是lncRNA MEG3在不久的未来将有可能成为临床肿瘤治疗的理想靶点。</p></sec><sec id="s9"><title>基金项目</title><p>泰州市科技支撑社会发展项目(2016-13)；泰州市人民医院院级课题(ZL201601)。</p></sec><sec id="s10"><title>文章引用</title><p>周 晶,田 野. 长链非编码RNA MEG3在肿瘤发生中的研究进展 Research Advancements of Long Non-Coding RNA MEG3 in Tumor[J]. 临床医学进展, 2018, 08(05): 454-459. https://doi.org/10.12677/ACM.2018.85075</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.25860-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Miyoshi, N., Wagatsuma, H., Wakana, S., et al. (2000) Identification of an Imprinted Gene. Meg3/Gtl2 and Its Human Homologne MEG3, First Mapped on Mouse Distal Chromosome 12 and Human Chromosome 14q. Genes to Cells, 5, 211-220. https://doi.org/10.1046/j.1365-2443.2000.00320.x</mixed-citation></ref><ref id="hanspub.25860-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, X., Zhou, Y., Mehta, K.R., et al. (2003) A Pituitary-Derived MEG3 Isoform Functions as a Growth Suppressor in Tumor Cells. Journal of Clinical Endocrinology and Metabolism, 88, 5119-5126.  
https://doi.org/10.1210/jc.2003-030222</mixed-citation></ref><ref id="hanspub.25860-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Gejman, R., Batista, D.L., Zhong, Y., et al. (2008) Selective Loss of MEG3 Expression and Intergenic Differentially Methylated Region Hypermethylation in the MEG3/DLKl Locus in Human Clinically Nonfunctioning Pituitary Adenomas. The Journal of Clinical Endocrinology &amp; Metabolism, 93, 4119-4125. https://doi.org/10.1210/jc.2007-2633</mixed-citation></ref><ref id="hanspub.25860-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Wilusz, J.E., Sunwoo, H. and Spector, D.L. (2009) Long Noncoding RNAs: Functional Surprises from the RNA World. Genes &amp; Development, 23, 1494-1504. https://doi.org/10.1101/gad.1800909</mixed-citation></ref><ref id="hanspub.25860-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Nagano, T. and Fraser, P. (2011) No-Nonsense Functions for Long Noncoding RNAs. Cell, 145, 178-181.  
https://doi.org/10.1016/j.cell.2011.03.014</mixed-citation></ref><ref id="hanspub.25860-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Tsang, W.P. Timothy, W.L., Albert, H.H., et al. (2007) Induction of Drug Resistance and Transformation in Human Cancer. RNA, 13, 890-898. https://doi.org/10.1261/rna.359007</mixed-citation></ref><ref id="hanspub.25860-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Ponting, C.P., Oliver, P.L. and Reik, W. (2009) Evolution and Functions of Long Noncoding RNAs. Cell, 136, 629-641. https://doi.org/10.1016/j.cell.2009.02.006</mixed-citation></ref><ref id="hanspub.25860-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Rinn, J.L., Kertesz, M., Wang, J.K., et al. (2007) Functional Demarcation of Active and Silent Chromatin Domains in Human HOX loci By noncoding RNAs. Cell, 129, 1311-1323. https://doi.org/10.1016/j.cell.2007.05.022</mixed-citation></ref><ref id="hanspub.25860-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Khalil, A.M., Guttman, M., Huarte, M., et al. (2009) Many Human Large Intergenic Noncoding RNAs Associate with Chromatin-Modifying Complexes and Affect Gene Expression. Proceedings of the National Academy of Sciences of the United States of America, 106, 667-672. https://doi.org/10.1073/pnas.0904715106</mixed-citation></ref><ref id="hanspub.25860-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Gupta, R.A., Shan, N., Wang, K.C., et al. (2010) Long Non-Coding RNA HOTAIR Reprograms Chromatin State to Promote Cancer Metastasis. Nature, 464, 1071-1076. https://doi.org/10.1038/nature08975</mixed-citation></ref><ref id="hanspub.25860-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Schmidt, L.H., Spieker, T., Koschmieder, S., et al. (2011) The Long Noncoding MALAT-1 RNA Indicates a Poor Prognosis in Non-Small Cell Lung Cancer and Induces Migration and Tumor Growth. Journal of Thoracic Oncology, 6, 1984-1992. https://doi.org/10.1097/JTO.0b013e3182307eac</mixed-citation></ref><ref id="hanspub.25860-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Menon, A.G., Rutter, J.L., von Sattel, J.P., et al. (1997) Frequent Loss of Chromosome 14 in Atypical and Malignant Meningioma: Identification of a Putative “Tumor Pro-gression” Locus. Oncogene, 14, 611-616.  
https://doi.org/10.1038/sj.onc.1200853</mixed-citation></ref><ref id="hanspub.25860-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Mutirangura, A., Pornthanakasem, W., Sriuranpong, V., et al. (1998) Loss of Heterozygosity on Chromosome 14 in Nasopharyngeal Carcinoma. International Journal of Cancer, 78, 153-156.  
https://doi.org/10.1002/(SICI)1097-0215(19981005)78:2&lt;153::AID-IJC5&gt;3.0.CO;2-Y</mixed-citation></ref><ref id="hanspub.25860-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Bando, T., Kato, Y., Ihara, Y., et al. (1999) Loss of Heterozygosity of 14q32 in Colorectal Carcinoma. Cancer Genetics and Cytogenetics, 111, 161-165. https://doi.org/10.1016/S0165-4608(98)00242-8</mixed-citation></ref><ref id="hanspub.25860-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Itoyama, T., Chaganti, R.S., Yamada, Y., et al. (2001) Cytogenetic Analysis and Clinical Significance in Adult T-Cell Leukemia/Lymphoma: A Study of 50 Cases from the Human T-Cell Leukemia Virus Type-1 Endemic Area, Nagasaki. Blood, 97, 3612-3620. https://doi.org/10.1182/blood.V97.11.3612</mixed-citation></ref><ref id="hanspub.25860-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Seitz, H., Royo, H., Bortolin, M.L., et al. (2004) A Large Imprinted microRNA Gene Cluster at the Mouse Dlk1-Gtl2 Domain. Genome Research, 14, 1741-1748. https://doi.org/10.1101/gr.2743304</mixed-citation></ref><ref id="hanspub.25860-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Zhou, Y., Zhong, Y., Wang, Y., et al. (2007) Activation of p53 by MEG3 Non-Coding RNA. The Journal of Biological Chemistry, 282, 24731-24742. https://doi.org/10.1074/jbc.M702029200</mixed-citation></ref><ref id="hanspub.25860-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, X., Rice, K., Wang, Y., Chen, W., Zhong, Y., Nakayama, Y., Zhou, Y. and Klibanski, A. (2010) Maternally Expressed Gene 3 (MEG3) Noncoding Ribonucleic Acid: Isoform Structure, Expression, and Functions. Endocrinology, 151, 939-947. https://doi.org/10.1210/en.2009-0657</mixed-citation></ref><ref id="hanspub.25860-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, X., Gejman, R., Mahta, A., Zhong, Y., Rice, K.A., Zhou, Y., Cheunsuchon, P., Louis, D.N. and Klibanski, A. (2010) Maternally Expressed Gene 3, an Imprinted Noncoding RNA Gene, Is Associated with Meningioma Pathogenesis and Progression. Cancer Research, 70, 2350-2358.</mixed-citation></ref><ref id="hanspub.25860-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Wang, P.J., Ren, Z.Q. and Sun, P.Y. (2012) Overexpression of the Long Non-Coding RNA MEG3 Impairs in Vitro Glioma Cell Proliferation. Journal of Cellular Biochemistry, 113, 1868-1874.</mixed-citation></ref><ref id="hanspub.25860-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Harris, S.L. and Levine, A.J. (2005) The p53 Pathway: Positive and Negative Feedback Loops. Oncogenem, 24, 2899-2908. https://doi.org/10.1038/sj.onc.1208615</mixed-citation></ref><ref id="hanspub.25860-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Zhao, J., Dahle, D., Zhou, Y., Zhang, X. and Klibanski, A. (2005) Hypermethylation of the Promoter Region Is Associated with the Loss of MEG3 Gene Expression in Human Pituitary Tumors. Journal of Clinical Endocrinology and Metabolism, 90, 2179-2186. https://doi.org/10.1210/jc.2004-1848</mixed-citation></ref><ref id="hanspub.25860-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Kagami, M., O’Sullivan, M.J., Green, A.J., Watabe, Y., Arisaka, O., Masawa, N., Matsuoka, K., Fukami, M., Matsubara, K., Kato, F., et al. (2010) The IG-DMR and the MEG3-DMR at Human Chromosome 14q32.2: Hierarchical Interaction and Distinct Functional Properties as Imprinting Control Centers. PLoS Genetics, 6, e1000992.  
https://doi.org/10.1371/journal.pgen.1000992</mixed-citation></ref><ref id="hanspub.25860-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Braconi, C., Kogure, T., Valeri, N., Huang, N., Nuovo, G., Costinean, S., Negrini, M., Miotto, E., Croce, C.M. and Patel, T. (2011) microRNA-29 Can Regulate Expression of the Long Non-Coding RNA Gene MEG3 in Hepatocellular Cancer. Oncogene, 30, 4750-4756. https://doi.org/10.1038/onc.2011.193</mixed-citation></ref><ref id="hanspub.25860-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Morenoc, S., Evansc, O., Zhan, X., et al. (2005) Novel Molecular Signaling and Classification of Human Clinically Non-Functional Pituitary Adenomas Identified by Gene Expression Profiling and Proteomic Analyses. Cancer Research, 65, 10214-10222. https://doi.org/10.1158/0008-5472.CAN-05-0884</mixed-citation></ref><ref id="hanspub.25860-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Losa, M., Franzin, A., Mangilif, et al. (2000) Proliferation Index of Nonfunctioning Pituitary Adenomas: Correlations with Clinical Characteristics and Long-Term Follow-Up Results. Neurosurgery, 47, 1313-1319.</mixed-citation></ref><ref id="hanspub.25860-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Louis, D.N., Wiestler, O.D. and Cavenee, W.K. (2007) World Health Organization Classification of Tumours of the Central Nervous System. IARC Press, Lyon.</mixed-citation></ref><ref id="hanspub.25860-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Bo, J., Yang, G., Huo, K., Jiang, H., Zhang, L., Liu, D. and Huang, Y. (2011) microRNA-203 Suppresses Bladder Cancer Development by Repressing bcl-w Expression. The FEBS Journal, 278, 786-792.  
https://doi.org/10.1111/j.1742-4658.2010.07997.x</mixed-citation></ref><ref id="hanspub.25860-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Kim, E.J., Lee, Y.S., Kim, Y.J., Kim, M.J., Ha, Y.S., Jeong, P., Lee, O.J. and Kim, W.J. (2010) Clinical Implications and Prognostic Values of Topoisomerase-II Alpha Expression in Primary Non-Muscle-Invasive Bladder Cancer. Urology, 75, 1516.e9-13.</mixed-citation></ref><ref id="hanspub.25860-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Kim, E.J., Yan, C., Ha, Y.S., Jeong, P., Yi Kim, I., Moon, S.K., Choi, Y.H. and Kim, W.J. (2012) Analysis of hOGG1 Genotype as a Prognostic Marker for Muscle Invasive Bladder Cancer: A Novel Approach Using Peptide Nucleic Acid-Mediated, Real-Time PCR Clamping. Urologic Oncology, 30, 673-679.  
https://doi.org/10.1016/j.urolonc.2010.07.008</mixed-citation></ref><ref id="hanspub.25860-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Ying, L., Huang, Y., Chen, H., Wang, Y., Xia, L., Chen, Y., Liu, Y. and Qiu, F. (2013) Downregulated MEG3 Activates Autophagy and Increases Cell Proliferation in Bladder Cancer. Molecular BioSystems, 9, 407-411.  
https://doi.org/10.1039/c2mb25386k</mixed-citation></ref><ref id="hanspub.25860-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Astuti, D., Latif, F., Wagner, K., Gentle, D., Cooper, W.N., Catchpoole, D., Grundy, R., Ferguson-Smith, A.C. and Maher, E.R. (2005) Epigenetic Alteration at the DLK1-GTL2 Imprinted Domain in Human Neoplasia: Analysis of Neuroblastoma, Phaeochromocytoma and Wilms’ Tumour. British Journal of Cancer, 92, 1574-1580.  
https://doi.org/10.1038/sj.bjc.6602478</mixed-citation></ref></ref-list></back></article>